The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksARDN.L Regulatory News (ARDN)

  • There is currently no data for ARDN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Preliminary Results - Year Ended 31 October 2014

14 Jan 2015 07:00

RNS Number : 0904C
Arden Partners plc
14 January 2015
 



 

Arden Partners plc

("Arden" or the "Group")

 

Preliminary results for the year ended 31 October 2014

 

Arden Partners plc (AIM: ARDN), the institutional stockbroking company, today announces preliminary results for the year ended 31 October 2014.

 

Financial highlights

· Revenue £8.0 million (2013: £10.1 million)

· Profit before tax £0.08 million (2013: £1.3 million)

· Underlying profit before tax* £0.15million (2013: £1.4million)

· Basic earnings per share 0.5p (2013: 4.7p)

· Proposed final dividend per share of 0.75p (2013: 1.75p)

 

* Profit before tax as adjusted for the effect of share based payments

 

Operational highlights

· Funds/Debt issuances for clients £457m

· Eighteen corporate transactions during the year

· Retained corporate clients 44

 

Commenting on the results and Arden's outlook, Peter Moon, Chairman, said:

 

"……following a slower than expected first half, I am pleased that the second half saw a rebound in revenue, allowing a small profit to be reported for the full year and the scope for the Board to recommend a final dividend. We remain focused on a strategy to develop the range of corporate and research services offered and to develop our corporate client base towards an optimum number..."

 

 

Arden Partners plc

James Reed-Daunter - Chief Executive Officer

Steve Wassell - Chief Operating Officer

 

020 7614 5900

Altium

Phil Adams / Sam Fuller

 

020 7484 4040

 

 

 

Chairman's Statement

After a slower than expected first half, the second half of the financial year saw a rebound in revenue, allowing a small profit to be reported for the full year.

 

As mentioned previously, the sector is undergoing structural change and commission revenues continue to decline. The Board continues to evolve the Arden business model to reflect these changes and to be more focussed on the range of corporate and research services offered. Proactive recruitment of personnel has been, and is being, undertaken to reflect this.

 

As was announced at the time, the Company bought back in aggregate 661,087 of its own Ordinary shares in November 2013 and subsequent to this, 200,000 of these shares were re-sold, with the balance being currently held, for the time being, in Treasury. The Board is minded in due course to make further market purchases of its own Ordinary shares into Treasury, with a view, ultimately, to cancelling these shares.

 

Although the scope for dividend payments, in the Board's view, has been limited during the year, in line with the Board's stated policy to reward stakeholders in the business and shareholders equally, a final dividend of 0.75 pence per share is recommended (interim dividend Nil per share), which if approved will result in a total dividend for the year of 0.75 pence per share (2013: 3.0 pence per share).

 

Finally, I would like to thank all concerned for their contribution during the year.

 

Peter Moon

Chairman

 

 

 

 

Chief Executive's Statement

After a difficult first half of the financial year I am pleased to report an improved performance and a good return to profit in the second half. The profit before tax result of £0.08m for the full year should be read within the context of a first half loss of £0.5m.

 

The above reflects the structural change happening in the industry, in particular to commission income driven by new top down guidelines and compliance regulations. Over the past 12 months we have been positioning the business to reflect this and will continue to do so in the first half of 2015.

 

We have invested into those areas of the business at the core of our strategy and believe we have a strong platform to deliver growing and sustainable revenues within the corporate finance division of the business. In support of this, it is encouraging to see our retained client base increasing in number to 44 at the year end (2013: 39).

 

Whilst the Board expects no significant recovery in commission revenues we do expect a better performance from market making and trading and this remains a cornerstone of our service offering to both institutional and corporate clients.

 

Financial Review

Revenue in the year ended 31 October 2014 was £8.0m compared to £10.1m in 2013. The underlying profit before tax was £0.15m compared to £1.4m in 2013. The profit before tax which is stated after charging share-based payments was £0.08m and compares to a profit before tax in 2013 of £1.3m.

 

The basic earnings per share was 0.5p compared to 4.7p in 2013. Arden's capital adequacy at the period end was significantly ahead of regulatory requirements.

 

At the year end the Company held 461,087 ordinary shares of 10 pence each in Treasury, the total value of which was £0.2m.

 

Equities Division

The equities division revenue fell from £5.1m in 2013 to £2.6m this year, further reflecting the reduced commission rates in the industry.

 

Trading Investments

As reported at the interim stage, certain long term investments saw a decline in mark to market book accounting values during the first half and whilst these are non-cash items, they resulted in a loss of £0.4m against a profit of £0.3m in 2013.

 

Corporate Finance

Corporate Finance fees, including retainers, increased to £5.3m in the year, from £5.1m in 2013.

 

During the year we were involved in 18 transactions, compared to 11 in 2013. In aggregate we placed £93m (2013: £283m) in equity, in addition to £364m (2013: Nil) of debt issuances, for corporate clients.

 

Outlook

The current year has started satisfactorily. Arden has completed one IPO to date and is mandated on several other corporate finance transactions which, subject to market conditions, will deliver in the first half.

 

Further out the corporate finance pipeline of work is very encouraging and although still market dependant, gives confidence for a significantly improved performance for the year.

 

Finally, I would like to take this opportunity to thank all our staff and clients for their continued support and commitment to the business.

 

James Reed-Daunter

Chief Executive Officer

 

 

 

 

Consolidated Statement of Comprehensive Income

For the year ended 31 October 2014

 

2014

2013

 

Note

£'000

£'000

Revenue

2

7,955

10,103

Administrative expenses

(7,936)

(8,829)

Profit from operations

19

1,274

Finance income

61

71

Finance expense

(5)

(4)

Profit before taxation

75

1,341

Income tax credit/(expense)

40

(351)

Profit after taxation

115

990

Other comprehensive income for the year:

Items that will or may be reclassified subsequently to profit or loss:

  Decrease in fair value of available for sale financial assets

 

 

 

(12)

 

 

 

(11)

Total comprehensive income for the year attributable to equity shareholders

103

979

 

 

Earnings per share

 

Basic

3

0.5p

4.7p

Diluted

3

0.5p

4.5p

 

 

 

 

Consolidated Statement of Financial Position

At 31 October 2014

 

 

2014

2014

2013

2013

 

Note

£'000

£'000

£'000

£'000

Assets

 

 

 

 

 

Non-current assets

 

 

 

 

 

Property, plant and equipment

 

 

43

 

92

Deferred tax asset

 

 

86

 

83

Total non-current assets

 

 

129

 

175

Current assets

 

 

 

 

 

Assets held at fair value

 

2,350

 

6,756

 

Available for sale financial assets

 

467

 

479

 

Trade and other receivables

 

4,770

 

18,578

 

Stock borrowing collateral

 

102

 

1,098

 

Cash and cash equivalents

 

8,282

 

3,733

 

Corporation tax asset

 

8

 

-

 

Total current assets

 

 

15,979

 

30,644

Total assets

 

 

16,108

 

30,819

Current liabilities

 

 

 

 

 

Financial liabilities held at fair value

 

(75)

 

(178)

 

Trade and other payables

 

(4,886)

 

(18,893)

 

Corporation tax liability

 

-

 

(315)

 

Total current liabilities

 

 

(4,961)

 

(19,386)

Total liabilities

 

 

(4,961)

 

(19,386)

Net assets

 

 

11,147

 

11,433

 

Shareholders' equity

 

 

 

 

 

Called up share capital

 

 

2,296

 

2,296

Capital redemption reserve

 

 

467

 

467

Share premium account

 

 

2,933

 

2,933

Employee Benefit Trust reserve

 

 

(849)

 

(1,046)

Available for sale reserve

 

 

(33)

 

(21)

Retained earnings

 

 

6,597

 

6,804

Total equity before deduction of own shares

 

 

11,411

 

11,433

Own shares

 

 

(264)

 

-

Total equity

 

 

11,147

 

11,433

 

 

 

 

Consolidated Statement of Cash Flows

For the year ended 31 October 2014

 

 

2014

2013

 

 

£'000

£'000

Operating activities before taxation

 

 

 

Profit before tax

 

75

1,341

Adjustments for:

 

 

 

Fair value adjustments of derivative financial assets

 

538

193

Depreciation of fixtures, fittings and computer equipment

 

82

123

Net interest receivable

 

(57)

(67)

Share based payments

 

77

76

Operating cash flow before changes in working capital

 

715

1,666

Decrease/(increase) in operating assets

 

18,673

(11,514)

(Decrease)/increase in operating liabilities

 

(14,111)

10,001

Cash generated from operations

 

5,277

153

Income taxes paid

 

(286)

(116)

Net cash flows from operating activities

 

4,991

37

Investing activities

 

 

 

Purchases of property, plant and equipment

 

(33)

(24)

Net interest received

 

57

67

Net cash flows from investing activities

 

24

43

Financing activities

 

 

 

Proceeds from the sale of own shares

 

222

332

Purchase of own shares

 

(322)

(1,322)

Issue of shares

 

-

25

Dividends paid to equity shareholders

 

(366)

(264)

Net cash flows from financing activities

 

(466)

(1,229)

Increase/(decrease) in cash and cash equivalents

 

4,549

(1,149)

Cash and cash equivalents at the beginning of the year

 

3,733

4,882

Cash and cash equivalents at the end of the year

 

8,282

3,733

 

 

 

 

Consolidated Statement of Changes in Equity

For the year ended 31 October 2014

Share

capital

Share

Premium

account

 

 

Capital Redemption Reserve

 

 

 

Own

shares

Employee

Benefit Trust

Reserve

 

 

Available

 for sale

 Reserve

Retained

earnings

Total

£'000

£'000

£'000

£'000

£'000

£'000

£'000

£'000

Balance at

1 November 2012

2,501

2,933

237

(661)

(607)

(10)

7,214

11,607

Profit for year

-

-

-

-

-

-

990

990

Revaluation of available for sale financial assets

-

-

-

-

-

(11)

-

(11)

Total comprehensive income for the year

-

-

-

-

-

(11)

990

979

Issue of shares

25

-

-

-

-

-

-

25

Purchase of own shares

-

-

-

(696)

(626)

-

-

(1,322)

Sale of own shares

-

-

-

299

-

-

-

299

Own shares cancelled

(230)

-

230

1,058

-

-

(1,058)

-

Share based payments

-

-

-

-

-

-

76

76

Sale of shares by Employee Benefit Trust to satisfy employee share schemes

-

-

-

-

187

-

(154)

33

Dividends paid to equity shareholders

-

-

-

-

-

-

(264)

(264)

Balance at

31 October 2013

2,296

2,933

467

-

(1,046)

(21)

6,804

11,433

Profit for year

-

-

-

-

-

-

115

115

Revaluation of available for sale financial assets

-

-

-

-

-

(12)

-

(12)

Total comprehensive income for the year

-

-

-

-

-

(12)

115

103

Purchase of own shares

-

-

-

(322)

-

-

-

(322)

Sale of own shares

-

-

-

58

-

-

-

58

Share based payments

-

-

-

-

-

-

77

77

Sale of shares by Employee Benefit Trust to satisfy employee share schemes

-

-

-

-

197

-

(33)

164

Dividends paid to equity shareholders

-

-

-

-

-

-

(366)

(366)

Balance at

31 October 2014

2,296

2,933

467

(264)

(849)

(33)

6,597

11,147

 

Notes

1. The capital redemption reserve represents the nominal value of shares that have been cancelled that were previously held as Own Shares.

 

2. Own Shares represents shares purchased to be held as treasury shares at historical cost.

 

3. The Employee Benefit Trust reserve represents shares held in the parent Company by the Arden Partners Employee Benefit Trust which is consolidated in these financial statements in accordance with the accounting policy in note 1. 

 

During the year 343,168 ordinary shares were issued from the employee benefit trust to satisfy employee share options (2013: 325,000).

 

 

 

 

NOTES

1) Basis of preparation

The financial information set out in this announcement has been prepared in accordance with the recognition and measurement principles of IFRS as endorsed for use in the European Union.

 

The financial information set out in this announcement does not constitute the Group's statutory accounts for the year ended 31 October 2014 or the year ended 31 October 2013 under the meaning of s434 Companies Act 2006, but is derived from those accounts.

Statutory accounts for the years ended 31 October 2014 and 31 October 2013 have been reported on by the Independent Auditors. 

 

The Independent Auditors' Report on the Annual Report and Financial Statements for the years ended 31 October 2014 and 31 October 2013 was unqualified, did not draw attention to any matters by way of emphasis, and did not contain a statement under 498(2) or 498(3) of the Companies Act 2006.

Statutory accounts for the year ended 31 October 2013 have been filed with the Registrar of Companies. The statutory accounts for the year ended 31 October 2014, prepared under IFRS, will be delivered to the Registrar in due course.

 

2) Revenue

Revenue is wholly attributable to the principal activity of the Group and arises solely within the United Kingdom.

 

 

 

2014

2013

 

 

£'000

£'000

Equities Division

 

2,689

5,046

Corporate Finance Division

 

5,266

5,057

Total revenue

 

7,955

10,103

 

Included within revenue of the Equities Division is a loss of £538,000 (2013: loss £190,000) relating to the fair value adjustment of derivatives held within assets that are fair valued through profit or loss.

 

The Directors are of the opinion that there are only two operating segments and while segment revenues are reviewed internally business resources are not allocated to segments for the purposes of deriving either profit or assets. In 2014, none of the Group's customers contributed 10% or more of the Group's revenue.

3) Earnings per Share

In addition to the basic earnings per share, underlying earnings per share has been shown because the Directors consider that this gives a more meaningful indication of the underlying performance of the Group. Where applicable, all adjustments are stated after taking into consideration current tax treatment ignoring deferred tax.

 

 

Year ended

31 October 2014

Year ended

31 October 2013

 

Pence per

Share

Numerator

£'000

Pence per

Share

Numerator

£'000

Basic earnings per share

0.5

115

4.7

990

Add: IFRS2 share-based payments

0.4

77

0.4

76

Underlying basic earnings

0.9

192

5.1

1,066

 

 

 

 

 

Diluted earnings per share

0.5

115

4.5

990

Add: IFRS2 share-based payments

0.4

77

0.4

76

Underlying diluted earnings

0.9

192

4.9

1,066

 

 

Year ended 

31 October 2014

 

Year ended 

31 October 2013

 

 

Number

 

Number

 

Denominator

 

 

 

 

Weighted average number of shares in issue for basic earnings calculation

20,818,253

 

21,008,130

 

Weighted average dilution for outstanding share options

1,132,883

 

740,730

 

Weighted average number for diluted earnings calculation

21,951,136

 

21,748,860

 

 

 

The 1,480,700 (2013: 1,823,868) shares held by the Arden Partners Employee Benefit and the 461,087 (2013: Nil) shares held in Treasury have been excluded from the denominator.

 

4) Annual Report and Accounts

Copies of the 2014 Report and Accounts will be posted to shareholders in due course. Copies will also be available from the Company's registered office and from the Company's website.

 

5) Dividend

The final dividend, if approved, will be paid on 27 March 2015 to shareholders on the register at close of business on 27 February 2015, with an ex-dividend date of 26 February 2015.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FR DGGDBUDBBGUX
Date   Source Headline
28th Apr 202210:15 amRNSOffer Update - Scheme of Arrangement - Effective
28th Apr 20227:30 amRNSSuspension - Arden Partners PLC
28th Apr 20227:00 amRNSNomad register change - Arden Partners Plc
27th Apr 20224:30 pmRNSOffer Update-Court Sanction, Scheme of Arrangement
27th Apr 20224:30 pmRNSOffer Update - Court Sanction of Scheme
21st Apr 20225:30 pmRNSInce Group
19th Apr 20222:00 pmRNSOffer Update – Extension of FCA approval
19th Apr 20222:00 pmRNSExtension of FCA Change of Control Approval
14th Apr 20227:00 amRNSOffer Update - Timetable for completion of Scheme
14th Apr 20227:00 amRNSOffer Update - Timetable for Completion of Scheme
12th Apr 202211:55 amRNSForm 8.5 (EPT/NON-RI)
11th Apr 20227:00 amRNSOffer update – Waiver of NOMAD condition
11th Apr 20227:00 amRNSOffer Update - Waiver of NOMAD Condition
8th Apr 20222:19 pmRNSPublication of Annual Report and Notice of AGM
7th Apr 20222:18 pmRNSHolding(s) in Company
7th Apr 20229:33 amRNSUpdate regarding the NOMAD condition
7th Apr 20227:00 amRNSUpdate Regarding the Nomad Condition
6th Apr 202211:41 amRNSForm 8.3 - Arden Partners plc
5th Apr 20227:00 amRNSAudited Results for the Year Ended 31 October 2021
18th Mar 202211:55 amRNSForm 8.5 (EPT/NON-RI)
15th Mar 202211:55 amRNSForm 8.5 (EPT/NON-RI) - AssetCo PLC
14th Mar 202211:55 amRNSForm 8.5 (EPT/NON-RI)
10th Mar 202211:55 amRNSForm 8.5 (EPT/NON-RI)
10th Mar 202210:20 amRNSForm 8.5 (EPT/NON-RI)
10th Mar 20229:48 amRNSForm 8.3 - Ince Group PLC
7th Mar 202211:55 amRNSForm 8.5 (EPT/NON-RI)
3rd Mar 202211:55 amRNSForm 8.5 (EPT/NON-RI)
17th Feb 202211:55 amRNSForm 8.5 (EPT/NON-RI)
11th Feb 202211:55 amRNSForm 8.5 (EPT/NON-RI)
10th Feb 202211:55 amRNSForm 8.5 (EPT/NON-RI)
9th Feb 202211:55 amRNSForm 8.5 (EPT/NON-RI)
4th Feb 20221:03 pmRNSForm 8.5 (EPT/NON-RI)
2nd Feb 202211:55 amRNSForm 8.5 (EPT/NON-RI)
1st Feb 202211:55 amRNSForm 8.5 (EPT/NON-RI)
27th Jan 20221:00 pmRNSForm 8.5 (EPT/NON-RI)
26th Jan 202211:55 amRNSForm 8.5 (EPT/NON-RI)
25th Jan 202211:55 amRNSForm 8.5 (EPT/NON-RI)
21st Jan 20227:00 amRNSApproval of the FCA condition
21st Jan 20227:00 amRNSFCA Approval of the Change of Control
20th Jan 202211:55 amRNSForm 8.5 (EPT/NON-RI)
19th Jan 20224:30 pmRNSResults of Arden court meeting & general meeting
19th Jan 20224:24 pmRNSResults of Court Meeting and General Meeting
18th Jan 202211:55 amRNSForm 8.5 (EPT/NON-RI)
17th Jan 202211:55 amRNSForm 8.5 (EPT/NON-RI)
13th Jan 202211:55 amRNSForm 8.5 (EPT/NON-RI)
20th Dec 20212:30 pmRNSPublication of Scheme Document
15th Dec 20217:00 amRNSExtension Of Irrevocable Undertakings
8th Dec 20218:00 amRNSExtension Of Irrevocable Undertakings
1st Dec 20212:03 pmRNSForm 8 (DD) - The Ince Group plc
30th Nov 202111:55 amRNSForm 8.5 (EPT/NON-RI)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.